Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statistical methods for a three-period crossover design in which high dose cannot be used first

K E Peace1, G G Koch

  • 1Biopharmaceutical Research Consultants, Inc. Ann Arbor, Michigan 48105.

Journal of Biopharmaceutical Statistics
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

One in four people may develop symptomatic hip osteoarthritis in his or her lifetime.

Osteoarthritis and cartilage·2010
Same author

Predictive tests for linked changes.

Statistics in medicine·2008
Same author

Design of vaccine equivalence/non-inferiority trials with correlated multiple binomial endpoints.

Journal of biopharmaceutical statistics·2006
Same author

Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities.

Annals of the rheumatic diseases·2006
Same author

Heart rate variability at rest and during mental stress in patients with coronary artery disease: differences in patients with high and low depression scores.

International journal of behavioral medicine·2005
Same author

Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.

Journal of biopharmaceutical statistics·2002

This study introduces a novel three-period crossover trial design and analysis for drug development, particularly for Alzheimer's disease treatments. It ensures dose escalation safety by analyzing intrapatient variability for unbiased treatment effect estimates.

Area of Science:

  • Clinical Trials Methodology
  • Pharmacological Research
  • Biostatistics

Background:

  • Investigator reluctance to administer high drug doses before low doses necessitates specialized trial designs.
  • Three-period crossover designs offer a structured approach to evaluate drug effects sequentially.
  • Alzheimer's disease drug trials require careful dose-ranging strategies to ensure patient safety and efficacy.

Purpose of the Study:

  • To develop and validate design and analysis methods for a specific three-period crossover trial.
  • To address the challenge of dose escalation in clinical trials by proposing a safe sequence.
  • To provide unbiased estimates of drug effects, including carryover, direct dose, and period effects.

Main Methods:

  • A three-period crossover trial design with sequences (D0, D1, D2), (D1, D0, D2), and (D1, D2, D0), where D0=placebo, D1=low dose, D2=high dose.

Related Experiment Videos

  • Randomization of patients to sequences in blocks that are integer multiples of 3.
  • Parametric and non-parametric analysis methods utilizing contrasts for intrapatient variability.

    • Main Results:

    • The proposed design and analysis methods provide unbiased estimates of pairwise differences between carryover, direct dose, and period effects.
    • The methods were illustrated using data from a clinical trial of Tacrine (0, 40, 80 mg/day) assessing cognitive function in Alzheimer's disease.
    • Intrapatient variability-focused contrasts ensure robust hypothesis testing for treatment effects.

    Conclusions:

    • The developed three-period crossover design and analysis are suitable for situations requiring cautious dose escalation.
    • This approach facilitates the evaluation of drug efficacy and safety, particularly in neurodegenerative disease trials.
    • The methods offer a statistically sound framework for analyzing complex dose-response relationships in clinical settings.